Key result
Combination immunosuppressive therapy and guideline-directed medical therapy improve overall and transplant-free survival in patients with giant cell myocarditis.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“When a patient with heart failure isn't getting better with treatment and is having those irregular heart rhythms, the ventricular tachycardia, that's a sign that it could be giant cell myocarditis. These telling symptoms help to sort the needle from the haystack.”
“What they saw was that the strength of the heart was quite weak.”
May inform management of this rare myocarditis; leaves open the need for randomized trials to confirm benefit.
Giant cell myocarditis is a rare, often rapidly progressive and potentially fatal, disease due to T-cell lymphocyte-mediated inflammation of the myocardium that typically affects young and middle-aged adults. Frequently, the disease course is marked by acute heart failure, cardiogenic shock, intractable ventricular arrhythmias, and/or heart block. Diagnosis is often difficult due to its varied clinical presentation and overlap with other cardiovascular conditions. Although cardiac biomarkers and multimodality imaging are often used as initial diagnostic tests, endomyocardial biopsy is required for definitive diagnosis. Combination immunosuppressive therapy, along with guideline-directed medical therapy, has led to a paradigm shift in the management of giant cell myocarditis resulting in an improvement in overall and transplant-free survival. Early diagnosis and prompt management can decrease the risk of transplantation or death, which remain common in patients who present with cardiogenic shock.
No takes yet. Share an insight, caveat, or question.
Bang et al. (2021) conducted a review in Giant cell myocarditis. Combination immunosuppressive therapy was evaluated. Combination immunosuppressive therapy and guideline-directed medical therapy improve overall and transplant-free survival in patients with giant cell myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: